

Supreme Court to Address Securities Fraud Pleading Standards

June 16, 2010 | Client Update

On June 14, 2010, the Supreme Court granted certiorari in a private securities fraud class action, *Matrixx Initiatives, Inc. v. Siracusano*. 560 U.S. ____ (Jun. 14, 2010) (No. 09-1156) (“*Matrixx*”). The case will present the Court with an opportunity to address conflicting standards in the United States Courts of Appeals for determining when a pharmaceutical manufacturer’s non-disclosure of reports of adverse effects from a medication may give rise to liability under Section 10(b) of the Securities and Exchange Act of 1934 and Securities and Exchange Commission Rule 10b-5 (collectively, “10b-5”).

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

Michael S. Flynn

+1 212 450 4766
michael.flynn@davispolk.com

Edmund Polubinski

+1 212 450 4695
edmund.polubinski@davispolk.com

Lawrence Portnoy

+1 212 450 4874
lawrence.portnoy@davispolk.com

Neal Potischman

+1 650 752 2021
neal.potischman@davispolk.com

James P. Rouhandeh

+1 212 450 4835
rouhandeh@davispolk.com

James H.R. Windels

+1 212 450 4978
james.windels@davispolk.com

This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.

Related materials

[Read the full update](#)